Cantor Fitzgerald Predicts FDMT FY2026 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of 4D Molecular Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of ($2.86) per share for the year. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02).

A number of other equities analysts have also recently issued reports on the stock. Bank of America dropped their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Barclays cut their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Chardan Capital reduced their price target on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Finally, Royal Bank of Canada cut their target price on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.56.

4D Molecular Therapeutics Price Performance

FDMT stock traded up $0.12 on Wednesday, reaching $4.48. 164,758 shares of the company traded hands, compared to its average volume of 826,288. The firm has a fifty day simple moving average of $3.37 and a 200-day simple moving average of $4.58. The company has a market cap of $207.54 million, a P/E ratio of -1.57 and a beta of 2.84. 4D Molecular Therapeutics has a one year low of $2.24 and a one year high of $28.93.

Institutional Trading of 4D Molecular Therapeutics

Several large investors have recently modified their holdings of FDMT. Decheng Capital LLC lifted its holdings in 4D Molecular Therapeutics by 0.5% in the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company's stock valued at $2,228,000 after acquiring an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of 4D Molecular Therapeutics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock worth $247,000 after buying an additional 2,925 shares during the last quarter. PNC Financial Services Group Inc. grew its position in 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after buying an additional 3,630 shares during the period. Rhumbline Advisers grew its position in 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after buying an additional 3,675 shares during the period. Finally, ProShare Advisors LLC increased its holdings in 4D Molecular Therapeutics by 30.1% during the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock valued at $91,000 after buying an additional 3,783 shares during the last quarter. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.